Connect with us

Technology

Astronomer Expands Global Footprint with Increased Presence in EMEA

Published

2 years ago

on

As Apache Airflow surpasses 3,000 contributors, Astronomer makes deeper investment to power business-critical data pipelines and AI initiatives across the region

LONDON, Sept. 18, 2024 /PRNewswire/ — Astronomer, the company behind Astro, the leading data orchestration and observability platform powered by Apache Airflow®, today announced it is expanding its EMEA presence, with plans to establish a permanent regional office soon. This strategic expansion is driven by the mature Airflow market in the region, the growing demand for Astro, and the company’s commitment to serving existing EMEA customers, such as Booking.com and Pleo.

Astronomer customers in EMEA will benefit from increased localized support and the wider Airflow community will see increased activity from Astronomer in the region. The company already has key Apache Airflow committers and engineers based across EMEA to enable customers to maximize the value of their Airflow investments and assist upcoming data initiatives. Astronomer just announced the private preview of Astro Observe, which allows any team using Airflow to now have access to an actionable view of the data supply chain and extends Astronomer beyond data orchestration into a platform for data operations. Additionally, Astronomer recently released dbt on Astro, marking the first platform expansion beyond Airflow and providing customers with a fully-managed method to deploy dbt and Airflow together.

“Data is the primary building block of analytics and AI, and drives the competitive advantage for the modern enterprise,” said Andy Byron, CEO, Astronomer. “Everything we do at Astronomer ensures that our customers are able to leverage their data to be the difference maker in executing their business strategy. This further commitment to EMEA means our current and future customers in the region will see world-class support for whatever their data strategy might be.”

Airflow is the industry’s de-facto standard for expressing pipelines and orchestrating data flows as code. Created at Airbnb as an open-source project in 2014, Airflow was brought into the Apache Software Incubator Program in 2016 and announced as a Top-Level Apache Project in 2019. Now, Airflow is widely recognized as the industry’s leading and most advanced workflow management and orchestration solution.

“Booking.com previously relied on OSS Airflow for our ML and analytics workflows, but quickly found that we required additional enterprise-grade features that only Astro could provide,” said Huy Dao, Director of Data Machine Learning Platform, Booking.com. “Astronomer has been a key partner in helping with the management of our data infrastructure, especially as we use Airflow for many GenAI initiatives like our AI Trip Planner. The scalability of our data systems along with the ability to enforce workflow ownership were key challenges and Astronomer has delivered on both those needs.”

Airflow has surpassed over 3,000 contributors, a higher total than other popular Apache open source software like Apache Spark® and Apache Kafka®. EMEA represents over 3.6 million monthly Airflow downloads, a figure that has continued to grow over time. This is consistent with the exponential growth noted in the 2024 State of Apache Airflow report, which found that last year Airflow saw a 67% year-over-year growth in annual Airflow downloads.

“As Astronomer has grown its investment in EMEA, I’ve seen two common themes emerge in early discussions with customers,” said Phil Duggan, EMEA Regional Vice President, Astronomer. “First, customers want a strategy that enables their business to move faster, to improve the reliability and trust of their data products, while accelerating development velocity and containing costs. Second, organizations want to put their data to work to gain a competitive edge in the evolving generative AI landscape and event-driven use cases. We are excited to help more EMEA companies tackle these common challenges with Astro, the only platform for complete orchestration of pipelines and data products they produce.”

“EMEA has continued to be a hotbed for Airflow innovation and broad adoption, so we are excited to expand Astronomer’s presence in the region to better serve our customers,” said Kaxil Naik, Senior Director of Engineering, Astronomer and Apache Airflow PMC Member & Core Committer. “Astro’s enterprise-grade features enables companies to place Airflow at the core of their data operations, ensuring the reliable delivery of mission-critical data pipelines and products, while also navigating Europe’s complex regulatory landscape, including compliance with emerging regulations like the Cyber Resilience Act.”

To receive a free Airflow health check from Astronomer, click here and visit the resources below.

Further Resources:

Register for the upcoming Airflow Forum in London on October 3Visit Astronomer’s booth X446 at Big Data London this week, September 18-19Receive a free Airflow Health CheckDownload Astronomer’s white paper on Full-stack Orchestration in the Age of the Data ProductTry Astro now with a 14-day Free Trial

About Astronomer

Astronomer empowers data teams to bring mission-critical software, analytics, and AI to life and is the company behind Astro, the industry-leading data orchestration and observability platform powered by Apache Airflow®. Astro accelerates building reliable data products that unlock insights, unleash AI value, and powers data-driven applications. Trusted by more than 700 of the world’s leading enterprises, Astronomer lets businesses do more with their data. To learn more, visit www.astronomer.io.

Apache® and Apache Airflow® are either registered trademarks or trademarks of the Apache Software Foundation in the United States and/or other countries. No endorsement by the Apache Software Foundation is implied by the use of these marks. All other trademarks are the property of their respective owners.

Media Contact:
Taylor Jones
press@astronomer.io

View original content:https://www.prnewswire.com/news-releases/astronomer-expands-global-footprint-with-increased-presence-in-emea-302251186.html

SOURCE Astronomer

Related Topics:
Continue Reading

Technology

HiTHIUM Partners with the University of Cambridge to Advance International Industry-Academia Collaboration in Long-Duration Energy Storage

Published

29 minutes ago

on

November 14, 2026

By

XIAMEN, China, Nov. 14, 2026 /PRNewswire/ — On November 12, the Global Energy Storage Colloquium was held in Xiamen. During the colloquium, HiTHIUM and the University of Cambridge signed a memorandum of understanding (MoU), establishing a strategic partnership. The two parties will collaborate on frontier scientific research, key technology innovation and industrial applications in battery energy storage, bringing academic research into closer alignment with industry needs and exploring new models for international industry-academia collaboration. The partnership aims to contribute to the advancement of global energy storage technology and the industry.

The UK has a strong track record in the development of modern battery technologies and fundamental research. The University of Cambridge is one of the world’s leading universities, with internationally recognized expertise in engineering, materials science and fundamental research. As a leading global energy storage technology company, HiTHIUM has long focused on energy storage technology development and commercialization. It continues to advance integrated research and innovation across the value chain, from high-capacity energy storage cells to long-duration energy storage systems and grid integration technologies.

The collaboration is intended to bring internationally leading academic research into closer engagement with innovation across China’s energy storage industry. The University of Cambridge’s strengths in fundamental science, materials research and engineering will offer new perspectives and approaches to key scientific questions and emerging technologies in energy storage. HiTHIUM will bring its experience in long-duration energy storage (LDES), product development and large-scale deployment, connecting research with real industry needs and application scenarios, and supporting the engineering validation and commercialization of research outcomes. By drawing on the strengths of both research and industry, the partnership will strengthen the links between frontier innovation and practical applications.

Under the cooperation plan, the two parties will establish joint management and research collaboration mechanisms, bringing together academic resources and corporate R&D capabilities. They will work together to plan research projects, facilitate scientific exchange and support the translation of research outcomes, strengthening connections between fundamental research, technology development and industrial applications so that innovation in energy storage can better serve industry needs.

The partnership also marks an important step in HiTHIUM’s efforts to expand its international innovation network. Building on this collaboration with the University of Cambridge, HiTHIUM will further strengthen academic exchanges and research partnerships with leading universities and research institutions around the world. By bringing together international research resources and talent, the company aims to encourage collaboration across disciplines and technology fields, explore the development of technologies such as LDES from a global perspective, and bring technical challenges and application needs from the front lines of industry into research and innovation. This will help research and industrial practice reinforce one another.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hithium-partners-with-the-university-of-cambridge-to-advance-international-industry-academia-collaboration-in-long-duration-energy-storage-302939492.html

SOURCE HiTHIUM

Continue Reading

Technology

The NYSE Welcomes vVARDIS as a Publicly Listed Company

Published

1 hour ago

on

November 14, 2026

By

NEW YORK, Nov. 14, 2026 /PRNewswire/ — vVARDIS (NYSE: VVVV) co-founders Dr. Haley Abivardi and Dr. Goly Abivardi aim to reshape the future of dental care with a drill-free treatment for the world’s #1 non-communicable disease: cavities.

vVARDIS Solves a Problem that Millions FaceTooth decay affects billions of people worldwide, and dental anxiety keeps millions from getting the care they need.vVARDIS is a Swiss dental technology company focused on changing the way early tooth decay is treated.vVARDIS has introduced a new approach that aims to treat decay earlier and more comfortably for patients.Its flagship product, Curodont® Repair Fluoride Plus, uses proprietary peptide technology to help repair early-stage tooth decay by supporting the natural remineralization of enamel — simply put No drill, No needle, or No filling.Tooth Decay is One of the Most Common Health Issues in the World2.5 billion people globally live with untreated tooth decay.Nearly 90% of U.S. adults have experienced tooth decay.Nearly 73% of U.S. adults report dental fear.21% avoid the dentist because of anxiety.The Story that Helped Shape vVARDISFor decades, treating early tooth decay often meant waiting until it worsened or getting a filling. The founders spent 25 years developing Curodont® Repair Fluoride Plus, a treatment that helps repair early tooth decay before it becomes a cavity.Curodont® gives dentists a way to treat early decay while making the experience easier and less intimidating for patients.The technology has already treated more than 2.5 million teethAvailable in more than 20% of U.S. dental practices

Click Here to Learn More about vVARDIS: https://www.youtube.com/watch?v=T1p9hUR5Glk

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/the-nyse-welcomes-vvardis-as-a-publicly-listed-company-302939487.html

SOURCE New York Stock Exchange

Continue Reading

Technology

Innovative Immunology Biotech Windward Bio Lists on Nasdaq

Published

4 hours ago

on

November 14, 2026

By

SHANGHAI, Nov. 14, 2026 /PRNewswire/ — Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day, up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners’ 11th IPO in 2026.

Qiming Venture Partners invested in Windward Bio’s inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026. Qiming also participated in this IPO financing round.

Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways. Led by a team with extensive expertise across discovery, development, and commercialization, Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines to improve clinical outcomes, reduce treatment burden and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

Windward Bio’s lead program, WIN378, is a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. WIN378 is currently being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in COPD. The company’s pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases. Windward Bio holds exclusive global rights (excluding Greater China and certain Asian countries) to WIN378 through a licensing agreement with Kelun-Biotech and Harbour BioMed, and has separately licensed WIN027 from Qyuns Therapeutics.

“Qiming Venture Partners invests in differentiated, globally competitive biotech innovation designed to address significant unmet needs for patients, and Windward Bio exemplifies this approach. We believe novel, long-acting biologics will reshape the treatment of severe chronic respiratory and skin diseases, and that WIN378 and WIN027 have the potential to expand and meaningfully improve the treatment options available to patients. In the hands of Luca and his team, with their expertise and proven track record, Windward is well-positioned to deliver on this potential, and we look forward to supporting the company through its next phase of growth,” said Alexander Sinclair Wilson, Principal at Qiming Venture Partners.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 630 fast-growing and innovative companies. Over 290 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 110 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.AI, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

 

View original content:https://www.prnewswire.com/news-releases/innovative-immunology-biotech-windward-bio-lists-on-nasdaq-302939481.html

SOURCE Qiming Venture Partners

Continue Reading

Trending